

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 044508-5001

Application No. 09/762,261

Applicants: Gerald Quinnan et al.

Page 1 of 1

Filing Date: February 5, 2001

Group Art Unit: 1653

## U.S. PATENT DOCUMENTS

Document No.	Date	Name	Class	Sub-Class	Filing Date

## FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

aa	<input checked="" type="checkbox"/>	Cotropia <i>et al.</i> (1996) A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates, <i>J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.</i> 12:221-232
ab	<input checked="" type="checkbox"/>	Hioe <i>et al.</i> (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies, <i>Int. Immunol.</i> 9:1281-1290
ac	<input checked="" type="checkbox"/>	Moore <i>et al.</i> (1993) Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains, <i>J. Virol.</i> 67:6136-6151
ad	<input checked="" type="checkbox"/>	Muster <i>et al.</i> (1993) A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1, <i>J. Virol.</i> 67:6642-6647
ae	<input checked="" type="checkbox"/>	Sabri <i>et al.</i> (1996) Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates, <i>AIDS Res. Hum. Retroviruses</i> , 12:855-858
af	<input checked="" type="checkbox"/>	Thali <i>et al.</i> (1993) Characterization of conserved human immunodeficiency virus type-1 gp120 neutralization epitopes exposed upon gp120-CD4, <i>J. Virol.</i> 67:3978-3988
ag	<input checked="" type="checkbox"/>	Thali <i>et al.</i> (1994) Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type-1 gp120 glycoprotein conferred by a gp41 amino acid change, <i>J. Virol.</i> 68:674-680
ah	<input checked="" type="checkbox"/>	Trkola <i>et al.</i> (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type-1, <i>J. Virol.</i> 70:1100-1108
ai	<input checked="" type="checkbox"/>	VanCott <i>et al.</i> (1997) Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type-1 isolates elicited by immunization with oligomeric gp160, <i>J. Virol.</i> 71:4319-4330
aj	<input checked="" type="checkbox"/>	Zwart <i>et al.</i> (1991) Immunodominance and antigenic variation of the principal neutralization domain of HIV-1, <i>J. Virol.</i> 181:481-489.

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket  
044508-5001Application No.  
Not assigned

09/762261

Applicants:  
Gerald V. Quinnan, Jr. *et al.*

Page 1 of 1

PTO Form 1449

Filing Date: February 5, 2001

Group Art Unit: Not assigned

## U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
SH	5,622,933	4/22/97	Sabatier <i>et al.</i>	514	16	6/15/94
SH	5,756,674	5/26/98	Katinger <i>et al.</i>	530	350	6/7/95
SH	5,439,809	8/8/95	Haynes <i>et al.</i>	435	69.3	6/15/92

## FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner	<i>Sharon H. Feltz</i>	Date Considered	6/16/2
----------	------------------------	-----------------	--------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.